The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177LuPSMA-617 and NOX66 (LuPIN).
 
Sarennya Pathmanandavel
No Relationships to Disclose
 
Megan Crumbaker
Honoraria - Bayer; Merck
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - MSD Oncology
 
Andrew O. Yam
No Relationships to Disclose
 
Andrew Nguyen
No Relationships to Disclose
 
Remy Niman
No Relationships to Disclose
 
Peter Wilson
No Relationships to Disclose
 
Shikha Sharma
No Relationships to Disclose
 
Maria Ayers
No Relationships to Disclose
 
Peter Eu
No Relationships to Disclose
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Louise Emmett
Honoraria - Astellas Pharma; AstraZeneca; Janssen Oncology; Mundipharma; Telix Pharmaceuticals
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)